400 related articles for article (PubMed ID: 31562770)
41. The Potential Effect of the 21st Century Cures Act on Drug Development.
Goble JA
J Manag Care Spec Pharm; 2018 Jul; 24(7):677-681. PubMed ID: 29952706
[TBL] [Abstract][Full Text] [Related]
42. Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact.
Brown JP; Douglas IJ; Hanif S; Thwaites RMA; Bate A
Value Health; 2021 Sep; 24(9):1241-1244. PubMed ID: 34452702
[TBL] [Abstract][Full Text] [Related]
43. Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review.
Seifu Y; Gamalo-Siebers M; Barthel FM; Lin J; Qiu J; Cooner F; Ruan S; Walley R
Ther Innov Regul Sci; 2020 Nov; 54(6):1436-1443. PubMed ID: 32514737
[TBL] [Abstract][Full Text] [Related]
44. Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.
Breckenridge AM; Breckenridge RA; Peck CC
Br J Clin Pharmacol; 2019 Sep; 85(9):1874-1877. PubMed ID: 31290181
[TBL] [Abstract][Full Text] [Related]
45. Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP).
Manchikanti L; Centeno CJ; Atluri S; Albers SL; Shapiro S; Malanga GA; Abd-Elsayed A; Jerome M; Hirsch JA; Kaye AD; Aydin SM; Beall D; Buford D; Borg-Stein J; Buenaventura RM; Cabaret JA; Calodney AK; Candido KD; Cartier C; Latchaw R; Diwan S; Dodson E; Fausel Z; Fredericson M; Gharibo CG; Gupta M; Kaye AM; Knezevic NN; Kosanovic R; Lucas M; Manchikanti MV; Mason RA; Mautner K; Murala S; Navani A; Pampati V; Pastoriza S; Pasupuleti R; Philip C; Sanapati MR; Sand T; Shah RV; Soin A; Stemper I; Wargo BW; Hernigou P
Pain Physician; 2020 Mar; 23(2):E85-E131. PubMed ID: 32214287
[TBL] [Abstract][Full Text] [Related]
46. The credibility of the FDA.
Blankfield RP
Eur J Prev Cardiol; 2013 Dec; 20(6):992-4. PubMed ID: 23867140
[No Abstract] [Full Text] [Related]
47. Qualitative and quantitative scrutiny by regulatory process: is the truth subjective or objective?
Dilsizian V; Narula J
JACC Cardiovasc Imaging; 2009 Aug; 2(8):1037-8. PubMed ID: 19679295
[No Abstract] [Full Text] [Related]
48. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations.
Briere JB; Bowrin K; Taieb V; Millier A; Toumi M; Coleman C
Curr Med Res Opin; 2018 Dec; 34(12):2125-2130. PubMed ID: 30217138
[TBL] [Abstract][Full Text] [Related]
49. Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims.
Girman CJ; Ritchey ME; McNeill AM; Sundell KA; Meyer RJ
Ther Innov Regul Sci; 2021 May; 55(3):561-567. PubMed ID: 33507517
[TBL] [Abstract][Full Text] [Related]
50. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
Thompson D
Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
[TBL] [Abstract][Full Text] [Related]
51. Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation.
Pulini AA; Caetano GM; Clautiaux H; Vergeron L; Pitts PJ; Katz G
Ther Innov Regul Sci; 2021 Jan; 55(1):228-238. PubMed ID: 32857313
[TBL] [Abstract][Full Text] [Related]
52. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
[TBL] [Abstract][Full Text] [Related]
53. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
[TBL] [Abstract][Full Text] [Related]
54. Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
Phillips CM; Parmar A; Guo H; Schwartz D; Isaranuwatchai W; Beca J; Dai W; Arias J; Gavura S; Chan KKW
Cancer; 2020 Apr; 126(8):1717-1726. PubMed ID: 31913522
[TBL] [Abstract][Full Text] [Related]
55. Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions.
Sheffield KM; Dreyer NA; Murray JF; Faries DE; Klopchin MN
J Comp Eff Res; 2020 Oct; 9(15):1043-1050. PubMed ID: 32914653
[TBL] [Abstract][Full Text] [Related]
56. The new FDA reality.
Waksman R
Cardiovasc Revasc Med; 2014 Jan; 15(1):1-2. PubMed ID: 24444470
[No Abstract] [Full Text] [Related]
57. How RWE Is Becoming the Real Deal.
Reinke T
Manag Care; 2018 Apr; 27(4):30-32. PubMed ID: 29701586
[TBL] [Abstract][Full Text] [Related]
58. How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers?
Berger ML; Crown W
Value Health; 2022 Feb; 25(2):167-170. PubMed ID: 35094788
[No Abstract] [Full Text] [Related]
59. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
[TBL] [Abstract][Full Text] [Related]
60. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model.
Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL
Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
